{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-240645","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2026-05-27T13:10:06+00:00","discovered_at":"2026-05-27T13:11:00.391862+00:00","generated_at":"2026-05-27T13:14:00.035938+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Jaguar Health regains Nasdaq Bid Price compliance; monitoring until May 2027","bullets":["Formal notice from Nasdaq on May 26, 2026: Jaguar complies with Bid Price Rule (closing bid ≥$1/sh).","Panel maintains jurisdiction until Sept 1, 2026; Mandatory Panel Monitor imposed until May 26, 2027.","If bid price <$1 for 30 consecutive trading days during monitoring, no 180-day grace period; delisting possible.","CEO Lisa Conte reported Q1 2026 net revenue +816% YoY and +527% QoQ, driven by out-license with Future Pak.","Company targets NDA for crofelemer formulation in mid-2027 and seeks development/commercialization partner."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-240645","json":"https://secwatch.observer/filing/0001193125-26-240645.json","markdown":"https://secwatch.observer/filing/0001193125-26-240645.md","text":"https://secwatch.observer/filing/0001193125-26-240645.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526240645/0001193125-26-240645-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526240645/d129501d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T13:14:00.035938+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001493152-26-025171","ticker":"MBOT","company_name":"Microbot Medical Inc.","filed_at":"2026-05-26T12:30:22+00:00","headline":"Microbot Medical receives Israeli regulatory approval for LIBERTY System, first outside U.S.","event_type":"regulatory","sec_items":["7.01","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 7.01, 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025171","json":"https://secwatch.observer/filing/0001493152-26-025171.json","markdown":"https://secwatch.observer/filing/0001493152-26-025171.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/883975/000149315226025171/0001493152-26-025171-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/883975/000149315226025171/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-064861","ticker":"RGTI","company_name":"Rigetti Computing, Inc.","filed_at":"2026-05-21T11:30:49+00:00","headline":"Rigetti signs LOI for up to $100M CHIPS Act award for quantum R&D; government to receive equity","event_type":"regulatory","sec_items":["3.02","8.01","7.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 7.01, 8.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-064861","json":"https://secwatch.observer/filing/0001104659-26-064861.json","markdown":"https://secwatch.observer/filing/0001104659-26-064861.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1838359/000110465926064861/0001104659-26-064861-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1838359/000110465926064861/tm2615300d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-251421","ticker":"GENC","company_name":"GENCOR INDUSTRIES INC","filed_at":"2026-06-01T20:09:26+00:00","headline":"Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251421","json":"https://secwatch.observer/filing/0001193125-26-251421.json","markdown":"https://secwatch.observer/filing/0001193125-26-251421.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/0001193125-26-251421-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/d135716d8k.htm"},"side_by_side_evidence":null},{"accession":"0001140361-26-023560","ticker":"NJR","company_name":"NEW JERSEY RESOURCES CORP","filed_at":"2026-06-01T20:03:21+00:00","headline":"NJNG files base rate case seeking $157.6M increase; offers 8.9% winter bill cut","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-023560","json":"https://secwatch.observer/filing/0001140361-26-023560.json","markdown":"https://secwatch.observer/filing/0001140361-26-023560.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/356309/000114036126023560/0001140361-26-023560-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/356309/000114036126023560/ef20075084_8k.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-026519","ticker":"ELTP","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2026-06-01T11:00:24+00:00","headline":"Elite Pharmaceuticals files ANDA for generic anticoagulant; $26B brand market, no generic available","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026519","json":"https://secwatch.observer/filing/0001493152-26-026519.json","markdown":"https://secwatch.observer/filing/0001493152-26-026519.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315226026519/0001493152-26-026519-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315226026519/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-062935","ticker":"ATNM","company_name":"Actinium Pharmaceuticals, Inc.","filed_at":"2026-05-29T21:10:41+00:00","headline":"Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062935","json":"https://secwatch.observer/filing/0001213900-26-062935.json","markdown":"https://secwatch.observer/filing/0001213900-26-062935.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/ea0292691-8k_actinium.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-068002","ticker":"REPL","company_name":"Replimune Group, Inc.","filed_at":"2026-05-29T13:56:10+00:00","headline":"Replimune to resubmit RP1 BLA for advanced melanoma; FDA agrees to prioritize review","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068002","json":"https://secwatch.observer/filing/0001104659-26-068002.json","markdown":"https://secwatch.observer/filing/0001104659-26-068002.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737953/000110465926068002/0001104659-26-068002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737953/000110465926068002/tm2615980d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001628280-26-039005","ticker":"BDX","company_name":"BECTON DICKINSON & CO","filed_at":"2026-05-29T12:39:28+00:00","headline":"BD resumes ChloraPrep shipments after voluntary hold; all final release testing acceptable","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039005","json":"https://secwatch.observer/filing/0001628280-26-039005.json","markdown":"https://secwatch.observer/filing/0001628280-26-039005.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/10795/000162828026039005/0001628280-26-039005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/10795/000162828026039005/bdx-20260529.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}